Trial record 1 of 4 for:    CUPID
Previous Study | Return to List | Next Study

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Celladon Corporation
ClinicalTrials.gov Identifier:
NCT00454818
First received: March 30, 2007
Last updated: August 1, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2012
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Publications:
Jessup M, Greenberg B, Mancini D, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID). A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure [published online ahead of print June 27, 2011]. Circulation 2011. doi:10.1161/CIRCULALTIONAHA.111.022889.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):